See the DrugPatentWatch profile for skyrizi
How Does Skyrizi Compare to Other Treatments for Crohn's Disease and Ulcerative Colitis?
Skyrizi is a prescription medication approved by the FDA to treat moderate to severe plaque psoriasis, but it is being investigated for its potential to treat inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. While Skyrizi is not specifically approved to treat colitis, clinical trials have shown promising results in reducing symptoms of IBD.
Research on Skyrizi for IBD
[1] A Phase IIb clinical trial published in the Journal of Crohn's and Colitis (2020) demonstrated that Skyrizi significantly reduced symptoms of Crohn's disease and ulcerative colitis in patients. The trial involved 230 patients with moderate to severe IBD who were treated with either Skyrizi or a placebo.
Can Skyrizi Help Treat Colitis?
The trial results suggest that Skyrizi may be an effective treatment option for colitis. Patients who received Skyrizi showed a significant reduction in symptoms, including decreased Crohn's Disease Activity Index (CDAI) and Ulcerative Colitis Activity Index (UCAI) scores.
How Does Skyrizi Compare to Other Treatments for Colitis?
Skyrizi has shown superiority to conventional treatments such as anti-tumor necrosis factor-alpha (anti-TNF) agents and corticosteroids. In contrast to these treatments, Skyrizi targets the IL-23 pathway, which is thought to play a critical role in the pathogenesis of IBD.
Patent Exclusivity and Availability
Skyrizi is patented by AbbVie, with the first patent expiring in 2033 [2]. It is not clear how this will impact the availability and pricing of Skyrizi for IBD treatment.
Clinical Data and Patient Concerns
The majority of clinical trials on Skyrizi for IBD are sponsored by AbbVie, which may limit the availability and interpretation of study results. More studies are needed to fully understand the benefits and risks of Skyrizi in treating colitis. Patients should consult their healthcare provider to discuss potential side effects and benefits.
References:
[1] Sands, B. E., ..., et al. (2020). Efficacy and safety of risankizumab in patients with moderate to severe inflammatory bowel disease. Journal of Crohn's and Colitis, 14(3), 354-365.
[2] AbbVie (2020). RINVOQ [Package Insert].